27744574|t|TGFβ Contributes to the Anti-inflammatory Effects of Tauroursodeoxycholic Acid on an Animal Model of Acute Neuroinflammation
27744574|a|The bile acid conjugate tauroursodeoxycholic acid (TUDCA) is a neuroprotective agent in various animal models of neuropathologies. We have previously shown the anti-inflammatory properties of TUDCA in an animal model of acute neuroinflammation. Here, we present a new anti-inflammatory mechanism of TUDCA through the regulation of transforming growth factor β (TGFβ) pathway. The bacterial lipopolysaccharide (LPS) was injected intravenously (iv) on TGFβ reporter mice (Smad-binding element (SBE)/Tk-Luc) to study in their brains the real-time activation profile of the TGFβ pathway in a non-invasive way. The activation of the TGFβ pathway in the brain of SBE/Tk-Luc mice increased 24 h after LPS injection, compared to control animals. This activation peak increased further in mice treated with both LPS and TUDCA than in mice treated with LPS only. The enhanced TGFβ activation in mice treated with LPS and TUDCA correlated with both an increase in TGFβ3 transcript in mouse brain and an increase in TGFβ3 immunoreactivity in microglia / macrophages, endothelial cells, and neurons. Inhibition of the TGFβ receptor with SB431542 drug reverted the effect of TUDCA on microglia / macrophages activation and on TGFβ3 immunoreactivity. Under inflammatory conditions, treatment with TUDCA enhanced further the activation of TGFβ pathway in mouse brain and increased the expression of TGFβ3. Therefore, the induction of TGFβ3 by TUDCA might act as a positive feedback, increasing the initial activation of the TGFβ pathway by the inflammatory stimulus. Our findings provide proof-of-concept that TGFβ contributes to the anti-inflammatory effect of TUDCA under neuroinflammatory conditions.
27744574	0	4	TGFβ	T116,T123	C0040690
27744574	24	49	Anti-inflammatory Effects	T080	C1515999
27744574	53	78	Tauroursodeoxycholic Acid	T109,T121	C0075857
27744574	85	97	Animal Model	T050	C0012644
27744574	101	106	Acute	T079	C0205178
27744574	107	124	Neuroinflammation	T046	C0021368
27744574	129	138	bile acid	T109,T123	C0005390
27744574	149	174	tauroursodeoxycholic acid	T109,T121	C0075857
27744574	176	181	TUDCA	T109,T121	C0075857
27744574	188	209	neuroprotective agent	T121	C0242912
27744574	221	234	animal models	T050	C0012644
27744574	238	254	neuropathologies	T091	C0876934
27744574	285	313	anti-inflammatory properties	T080	C1515999
27744574	317	322	TUDCA	T109,T121	C0075857
27744574	329	341	animal model	T050	C0012644
27744574	345	350	acute	T079	C0205178
27744574	351	368	neuroinflammation	T046	C0021368
27744574	393	420	anti-inflammatory mechanism	T080	C1515999
27744574	424	429	TUDCA	T109,T121	C0075857
27744574	442	499	regulation of transforming growth factor β (TGFβ) pathway	T044	C1155369
27744574	505	514	bacterial	T080	C0521009
27744574	515	533	lipopolysaccharide	T109	C0023810
27744574	535	538	LPS	T109	C0023810
27744574	544	566	injected intravenously	T061	C1737200
27744574	575	579	TGFβ	T116,T123	C0040690
27744574	580	593	reporter mice	T015	C0025929
27744574	595	615	Smad-binding element	T116,T123	C1571580
27744574	617	620	SBE	T116,T123	C1571580
27744574	633	638	study	T062	C2603343
27744574	648	654	brains	T023	C0006104
27744574	659	687	real-time activation profile	T059	C1979963
27744574	695	707	TGFβ pathway	T044	C1155363
27744574	713	725	non-invasive	T169	C0205303
27744574	735	765	activation of the TGFβ pathway	T040	C2244559
27744574	773	778	brain	T023	C0006104
27744574	782	797	SBE/Tk-Luc mice	T015	C0025929
27744574	819	822	LPS	T109	C0023810
27744574	823	832	injection	T061	C1533685
27744574	846	861	control animals	T008	C1511501
27744574	868	878	activation	T052	C1879547
27744574	879	883	peak	T080	C0444505
27744574	905	909	mice	T015	C0025929
27744574	910	917	treated	T169	C1522326
27744574	928	931	LPS	T109	C0023810
27744574	936	941	TUDCA	T109,T121	C0075857
27744574	950	954	mice	T015	C0025929
27744574	955	962	treated	T169	C1522326
27744574	968	971	LPS	T109	C0023810
27744574	991	1006	TGFβ activation	T040	C2244559
27744574	1010	1014	mice	T015	C0025929
27744574	1015	1022	treated	T169	C1522326
27744574	1028	1031	LPS	T109	C0023810
27744574	1036	1041	TUDCA	T109,T121	C0075857
27744574	1066	1074	increase	T169	C0442805
27744574	1078	1094	TGFβ3 transcript	T116,T123	C0040690
27744574	1098	1103	mouse	T015	C0025929
27744574	1104	1109	brain	T023	C0006104
27744574	1117	1125	increase	T169	C0442805
27744574	1129	1134	TGFβ3	T116,T123	C0040690
27744574	1135	1151	immunoreactivity	T044	C0597879
27744574	1155	1164	microglia	T025	C0206116
27744574	1167	1178	macrophages	T025	C0024432
27744574	1180	1197	endothelial cells	T025	C0225336
27744574	1203	1210	neurons	T025	C0027882
27744574	1212	1222	Inhibition	T044	C0021469
27744574	1230	1243	TGFβ receptor	T116,T129,T192	C0076930
27744574	1249	1262	SB431542 drug	T109,T121	C1137338
27744574	1286	1291	TUDCA	T109,T121	C0075857
27744574	1295	1304	microglia	T043	C0007613
27744574	1307	1329	macrophages activation	T043	C2248379
27744574	1337	1342	TGFβ3	T116,T123	C0040690
27744574	1343	1359	immunoreactivity	T044	C0597879
27744574	1367	1390	inflammatory conditions	T046	C0021368
27744574	1392	1401	treatment	T169	C1522326
27744574	1407	1412	TUDCA	T109,T121	C0075857
27744574	1434	1460	activation of TGFβ pathway	T044	C1155363
27744574	1470	1475	brain	T023	C0006104
27744574	1480	1489	increased	T081	C0205217
27744574	1494	1504	expression	T045	C1171362
27744574	1508	1513	TGFβ3	T116,T123	C0040690
27744574	1530	1539	induction	T169	C0205263
27744574	1543	1548	TGFβ3	T116,T123	C0040690
27744574	1552	1557	TUDCA	T109,T121	C0075857
27744574	1592	1602	increasing	T169	C0442808
27744574	1615	1645	activation of the TGFβ pathway	T040	C2244559
27744574	1653	1665	inflammatory	T169	C0333348
27744574	1666	1674	stimulus	T067	C0234402
27744574	1719	1723	TGFβ	T116,T123	C0040690
27744574	1743	1767	anti-inflammatory effect	T080	C1515999
27744574	1771	1776	TUDCA	T109,T121	C0075857
27744574	1783	1811	neuroinflammatory conditions	T046	C0021368